Clearsense, Inc — SEC Form D Filing

Clearsense, Inc filed an SEC Form D on April 22, 2026, reporting $5.00M raised in Healthcare Technology.

Form D filing details

Filing
SEC Form D
Filing date
April 22, 2026
Amount reported
$5.00M
Round stage
Series A
Industry
Healthcare Technology
Website
https://clearsense.com/

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Health systems face challenges with scattered and disparate healthcare data, leading to inefficiencies and unnecessary costs.

Solution

Clearsense provides a platform called 1Clearsense that unifies and manages disparate healthcare data into a more accessible and secure format, improving outcomes, reducing costs, and enhancing operational efficiency.

Verdict

": "Investors said yes because Clearsense presented a vision for solving a pervasive issue in healthcare data management, not because there was clear evidence of market traction or demand. They were implicitly betting on the urgency of addressing inefficiencies in health systems, which remain a persistent problem. However, the limited upside is that without a well-defined buyer or budget owner, the scalability of the solution could be a gamble on market adoption rather than guaranteed revenue.", "Signal Cards": { "Narrative Clarity": "Low — The absence of specific buyer and budget owner details makes pricing the round difficult. (Observed)", "Market Legibility": "Medium — The problem is recognized, but the lack of market specifics complicates investor understanding. (Inferred)", "Differentiation": "Low — Many healthcare data solutions exist, and without unique selling points, it’s hard to distinguish Clearsense from competitors. (Observed)", "Defensibility": "Weak — The technology may lack barriers to entry, raising concerns about sustaining a competitive advantage. (Observed)" }, "Narrative Fingerprint": { "Clear buyer identified": "No", "Budget owner named": "No", "Cost replacement articulated": "No", "Regulatory tailwinds present": "No", "Technological novelty": "No", "Expansion narrative beyond wedge": "No" }, "Competitive Narrative Context": { "Crowded themes": [ "Data unification and management in healthcare.", "Reducing operational inefficiencies through technology.", "Improving patient outcomes via data analytics." ], "Differentiation warnings": [ "Reliance on the broad appeal of healthcare data solutions without proving unique advantages.", "Failure to define a specific market segment may dilute the narrative.", "Lack of evidence supporting urgency may lead investors to question commitment." ], "White-space opportunities": [ "Niche solutions targe

Source: SEC EDGAR Form D filing